Form 4: Director Clay Siegall Increases Stake in Shattuck Labs
Insider Transaction Report
Director Clay B. Siegall purchased 62,500 shares of Shattuck Labs, Inc. common stock as part of a recent underwritten offering.
Summary
- Director Clay B. Siegall acquired 62,500 shares of Shattuck Labs, Inc. (STTK) common stock.
- The purchase was executed at a price of $4.00 per share.
- The transaction occurred on June 9, 2026, in connection with an underwritten offering that closed on June 11, 2026.
- Following this transaction, the director's total beneficial ownership increased to 318,608 shares.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as director-level insider buying typically indicates confidence in the company's strategic direction.
Positives
- Insider confidence is demonstrated by the director's decision to purchase additional shares in the open market during an underwritten offering.
- The purchase increases the alignment of interests between the director and shareholders.
Negatives
- None identified in this filing.
Risks
- Investment in biotechnology companies involves inherent risks related to clinical trial outcomes and regulatory approvals.
Future Outlook
The filing does not provide specific forward-looking guidance, but notes the purchase was part of an underwritten offering.
Industry Context
StockSavvy.ai notes that insider buying during an underwritten offering is often viewed as a positive signal of management's belief in the company's long-term valuation and pipeline potential.
Comparison to Industry Standards
- Insider participation in follow-on offerings is a common practice in the biotechnology sector to signal stability to institutional investors.
Stakeholder Impact
- Shareholders may interpret the director's purchase as a vote of confidence in the company's current valuation.
Next Steps
- Continued monitoring of insider activity and future clinical trial updates from Shattuck Labs.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Date of the share purchase transaction. |
| 06/11/2026 | Closing date of the underwritten offering and filing date of the Form 4. |
Keywords
Shattuck Labs, STTK, Insider Trading, Clay Siegall, Biotech, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.